

NYRx Drug Class Coverage Overview: Sodium Glucose Co-Transporter 2 Inhibitors

NYRx Preferred Drug

Drugs in the Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors drug class are included on the [NYRx Preferred Drug List](#) (PDL) and are subject to prior authorization (PA) requirements.

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
VI. Endocrine and Metabolic Agents		
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors ST		
Farxiga [®] Invokamet [®] ¹ Invokamet [®] XR ¹ Invokana [®] Jardiance [®] Synjardy [®] ¹ Synjardy [®] XR ¹ Trijardy [®] XR ¹ Xigduo [®] XR ¹	Inpefa [™] Segluromet [®] Steglatro [®]	STEP THERAPY (ST) <ul style="list-style-type: none"> Requires trial with metformin with or without insulin prior to initiating SGLT2 therapy unless there is a contraindication, or the drug is being used for an FDA-approved Medicaid covered indication other than, or in addition to, Type 2 Diabetes.

Coverage Criteria Requirements

- Preferred drugs will not require PA if the required coverage parameters, as outlined in the [NYRx Preferred Drug List](#), are found in the member’s Medicaid claim history at the time of pharmacy claim submission. Non-preferred drugs will require PA.
- Step Therapy requirements outlined in the PDL are in response to the NYRx Drug Utilization Review Board (DURB) recommendation based on FDA labeling and/or clinical practice guidelines and include:
 - Trial with metformin with or without insulin prior to initiating SGLT2 Inhibitors therapy unless there is a contraindication, or the drug is being used for an FDA-approved Medicaid-covered indication other than, or in addition to, Type 2 Diabetes.

What Pharmacy Providers Need to Do

Pharmacy providers should become familiar with the SGLT2 Inhibitors coverage criteria and the [NYRx Preferred Drug List](#) and incorporate this information when discussing the need for PA with prescribers.

What Prescribers Need to Do

Prescribers should become familiar with the SGLT2 Inhibitors coverage criteria and the [NYRx Preferred Drug List](#) and incorporate this information when prescribing for Medicaid members.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Call and Fax Guide](#)
- [NYRx Step Therapy](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays, or by email at NYRxEO@magellanhealth.com.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Office hours are also available by appointment. For more information, email NYRxEO@magellanhealth.com or visit the [NYRx Education & Outreach website](#).